ClinicaliQ Trial Snapshot
- Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren’s Disease With Moderate to Severe Systemic Disease Activity — Recruiting • Phase II • NCT06979531.
- IMVT-1402 tested against placebo in adults with moderate-to-severe primary Sjögren's disease to assess whether it improves symptoms and is safe.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a Phase 2b, multicenter, randomized, double-blinded, placebo-controlled study to assess the efficacy and safety of IMVT-1402 in adult participants with moderate to severe systemic primary Sjogren's disease (SjD). Conditions: Primary Sjögren's Syndrome Interventions: IMVT-1402, Placebo Lead Sponsor: Immunovant Sciences GmbH Planned Enrollment: 180 participants